Severe acute pancreatitis (SAP) is a critical disease caused by diffuse hemorrhage of the pancreas and combined with necrosis of surrounding tissues. 1 Conventional symptomatic treatments such as pain relief, gastrointestinal pressure reduction, correction of water and electrolyte and acid-base disorder play an important role in controlling the secretion of gastric juice and pancreatic juice in patients with severe acute pancreatitis, but the therapeutic effect is not ideal. Somatostatin is a kind of peptide hormone, which has an effect on the inhibition of the secretion of growth hormone and gastrointestinal hormone. Studies have shown that early use of somatostatin can alleviate inflammation and improve immune function in SAP patients, but the impact on mortality and morbidity of patients needs further study. 2 Pantoprazole is a new proton pump inhibitor, which can reduce the secretion of gastric acid and pepsin and effectively improve the gastrointestinal PH value of patients, thus blocking the secretion of physiological protease, reducing the secretion of pancreas body, and exerting a high acidsuppressing effect. Pantoprazole can reduce inflammatory cell infiltration and necrosis of acinar cells in SAP patients, which has been shown in a study. 3 Serum levels of C-reactive protein (CRP) and intercellular adhesion molecule-1 (ICAM-1) are important experimental indicators for judging the severity of pancreatitis and detecting pancreatic necrosis. The objective of this study was to investigate the effects of somatostatin combined with pantoprazole on serum C-reactive protein and intercellular adhesion molecule-1 in patients with severe acute pancreatitis.
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This experimental study was carried out at the Department of Hepatobiliary Surgery, Guizhou Province People's Hospital, China, from February 2016 to April 2018. A total of 82 SAP patients were enrolled in this study. The inclusion criteria were that patients diagnosed as SAP, over 18 years old, and the time from onset to admission was less than 48 hours. Patients with severe heart, lung, liver and kidney diseases, Diabetes, hematological diseases and severe hyperlipidemia and patients who took immunosuppressive agents and hormones for a long time were excluded. The patients were randomly divided into group A and group B with 41 cases in each group. Both groups were treated with fasting, maintaining acid-base balance and electrolyte balance, gastrointestinal decompression, cefuroxime and levofloxacin to control infection and inhibiting pancreatic secretion. Nutritional support and blood volume supplementation were used. Group A was treated with pantoprazole, i.e. 40 mg pantoprazole was added into 5% 100 mL of glucose injection and intravenously dripped twice a day. Group B was treated with somatostatin combined with pantoprazole, i.e. on the basis of group A, somatostatin was added. For the first time, 250 g somatostatin was injected intra-venously, and then 3000 g somatostatin +500 mL 0.9% sodium chloride injection was given by micro-intravenous pump at a speed of 250 g per hour, twice a day. The course of treatment in both groups was 7 days. The time of abdominal pain relief, intestinal function recovery and ventilator weaning in group B were shorter than those in group A (all p<0.001, Table I ). Before treatment, there was no significant difference in the levels of serum CRP and ICAM-1 between the two groups (p=0.657, 0.835), while the levels of serum CRP and ICAM-1 in group B were lower than those in group A (both p<0.001, Table I ) after treatment.
Some studies have found that somatostatin is more effective than pantoprazole in inhibiting gastric acid secretion in patients with peptic ulcer bleeding. 4 As the action mechanisms of somatostatin and pantoprazole are different, the combination of the two may play a better therapeutic effect. Therefore, this study investigated the therapeutic effect of somatostatin combined with pantoprazole sodium in the treatment of SAP. This study showed that the time of abdominal pain relief, intestinal function recovery and ventilator weaning in group B were better than those in group A. It is suggested that the combination of somatostatin and pantoprazole has a better therapeutic effect on SAP.
Halonen et al. have shown that excessive release of inflammatory mediators and cell factors play an important role in the development of SAP. 5 CRP is a marker of body injury or acute or chronic inflammation. ICAM-1 can mediate adhesion of cell-to-cell or cell-toextracellular matrix and play an important role in many biological processes such as inflammation. Studies have shown that serum ICAM-1 is an early diagnostic and predictive indicator of SAP. 6 The results showed that somatostatin combined with pantoprazole could effectively reduce serum CRP and ICAM-1 levels in SAP patients, which might be a mechanism that somatostatin combined with pantoprazole could effectively improve SAP symptoms.
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